Literature DB >> 7542499

Primitive human hematopoietic precursors express Bcl-x but not Bcl-2.

J R Park1, I D Bernstein, D M Hockenbery.   

Abstract

Bcl-2 and its homologue, bcl-xL, encode membrane-associated proteins that suppress programmed cell death of hematopoietic cell lines after growth factor withdrawal, and are expressed in hematopoietic precursor cells. To better understand the maintenance of long-term survival in the hematopoietic stem cell population, we evaluated the expression patterns of Bcl-2 and Bcl-x in primitive hematopoietic precursor populations. Hematopoietic precursor cells expressing CD34 (CD34+) and lacking maturation-linked surface antigens (lin-) were isolated from adult human bone marrow using two-color immunofluorescence cell sorting and fractionated on the basis of forward light scatter characteristics into blast-sized and small to medium lymphocyte-sized cell populations. Bcl-2 expression was shown in 78% to 90% of CD34+ lin- blast-sized cells versus less than 10% of small to medium lymphocyte-sized CD34+ lin- cells by immunohistochemical analysis. Small to medium lymphocyte-sized CD34+ lin- cells were further enriched for primitive precursors by selecting cells that lacked expression of CD38 (CD34+ lin- CD38-). In parallel experiments, only 1% to 4% of CD34+ lin- CD38- cells expressed Bcl-2, whereas 45% to 56% of these cells generated colony-forming cells. In contrast, > or = 94% of cells in all bone marrow subpopulations studied expressed Bcl-x protein. Both alternatively spliced bcl-x transcripts, bcl-xL and bcl-xs, were present. Our data show that the most primitive hematopoietic precursors express Bcl-x but not Bcl-2. Thus, the functional bcl-2 homologue, bcl-xL, may be essential for the long-term survival of the hematopoietic stem cell population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542499

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Bcl-2 and apoptosis in chronic lymphocytic leukemia.

Authors:  Aaron D Schimmer; Irene Munk-Pedersen; Mark D Minden; John C Reed
Journal:  Curr Treat Options Oncol       Date:  2003-06

2.  Markers of apoptosis in stage IB squamous cervical carcinoma.

Authors:  G Van de Putte; R Holm; A K Lie; M Baekelandt; G B Kristensen
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

3.  Imatinib spells BAD news for Bcr/abl-positive leukemias.

Authors:  Scott H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

4.  Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.

Authors:  G Deng; C Lane; S Kornblau; A Goodacre; V Snell; M Andreeff; A B Deisseroth
Journal:  Mol Med       Date:  1998-03       Impact factor: 6.354

5.  Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.

Authors:  W C Liles; P A Kiener; J A Ledbetter; A Aruffo; S J Klebanoff
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

Review 6.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Authors:  Fevzi F Yalniz; William G Wierda
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

Review 7.  Importance of the Bcl-2 family in cell death regulation.

Authors:  T J McDonnell; A Beham; M Sarkiss; M M Andersen; P Lo
Journal:  Experientia       Date:  1996-10-31

8.  Bcl2 enhances induced hematopoietic differentiation of murine embryonic stem cells.

Authors:  Yan-Yi Wang; Xingming Deng; Lijun Xu; Fengqin Gao; Tammy Flagg; W Stratford May
Journal:  Exp Hematol       Date:  2007-11-26       Impact factor: 3.084

9.  The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans.

Authors:  M C Mackey; A A G Aprikyan; D C Dale
Journal:  Cell Prolif       Date:  2003-02       Impact factor: 6.831

10.  Severe congenital neutropenia: genetics and pathogenesis.

Authors:  Laurence A Boxer
Journal:  Trans Am Clin Climatol Assoc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.